Feasibility Study: Evaluation of the Ulthera® System for Improvement of Surgical Scars.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Surgical Scar
- Sponsor
- Ulthera, Inc
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- The primary endpoint is improvement in appearance of scar tissue as determined by a masked, qualitative assessment of photographs at 90-days post-treatment time points comparing the treated to untreated side of the scar.
- Status
- Terminated
- Last Updated
- 8 years ago
Overview
Brief Summary
Up to 25 subjects will be enrolled. Enrolled subjects will received on Ulthera® treatment on one half of their surgical scar. Follow up visits will occur at 30, 90 and 180 days after treatment. Study images will be obtained before treatment, immediately after treatment and at each follow-up visit.
Detailed Description
This is a prospective, single-center, pilot clinical trial to evaluate the efficacy of the Ulthera® system to improve the appearance of scar tissue on the neck, abdomen or back. Changes from baseline of the Patient Observer Scar Assessment Scale score will be assessed at study follow-up visits. Images will be obtained prior to treatment and at each follow up visit. Patient satisfaction questionnaires will also be obtained.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female, age 18 to 70 years.
- •Subject in good health.
- •Subjects will have regularly shaped surgical scars on the chest, abdomen or back that are at least 4 cm long, are no wider than 1 cm, and are at least 6 months old.
- •Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.
- •Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
- •Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at the Screening Visit and be willing and able to use an acceptable method of birth control (e.g. barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following conditions is documented on the medical history:
- •Postmenopausal for at least 12 months prior to study;
- •Without a uterus and/or both ovaries; or
- •Bilateral tubal ligation at least six months prior to study enrollment.
Exclusion Criteria
- •Presence of an active systemic or local skin disease that may affect wound healing.
- •Allergy to any pain medications used in the study (lidocaine, NSAIDs, narcotics, etc.)
- •Severe solar elastosis.
- •Open wounds or lesions in the area(s) to be treated.
- •Severe or cystic acne on the area(s) to be treated.
- •Presence of a metal stent or implant in the area(s) to be treated.
- •Inability to understand the protocol or to give informed consent.
- •Microdermabrasion, or prescription level glycolic acid treatment to the treatment area(s) within three months prior to study participation or during the study.
- •Intralesional kenalog in the past 6 months.
- •History of chronic drug or alcohol abuse.
Outcomes
Primary Outcomes
The primary endpoint is improvement in appearance of scar tissue as determined by a masked, qualitative assessment of photographs at 90-days post-treatment time points comparing the treated to untreated side of the scar.
Time Frame: 90 days
Masked assessors will compare baseline images to images obtained at the 90 day follow up time point in a blinded fashion.
Secondary Outcomes
- 2. Difference in POSAS score as assessed by the patient using the Patient Observer Scar Assessment Scale (POSAS) between the treated and untreated half of the scar at 90-days post-treatment compared to baseline.(90 Days)
- 3. Patient satisfaction questionnaire at the 90-day follow-up visit.(90 Days)
- 1. Improvement in POSAS score of the treated half of the scar as assessed by the observer using the Patient and Observer Scar Assessment Scale (POSAS) at 90-days post-treatment compared to baseline.(90 Days)